



Press Release

Stockholm, December 20, 2000

Invest Receive invests \$ 20 million in Molecular Staging

Invest Receive has, via its wholly owned subsidiary Invest Receive Growth Capital, invested \$20 million in the life sciences tool company Molecular Staging. The total Series D preferred stock financing was \$41.25 million. OrbiMed, CIBC Capital Partners and Cooper Hill Partners were other investors in this round.

Molecular Staging Inc. is a private, life sciences tool company developing a portfolio of technologies for the detection and measurement of proteins and nucleic acids across a broad range of applications, including proteomics, genomics, pharmacogenomics and diagnostics. MSI's core technology is Rolling Circle Amplification Technology (RCAT™), an isothermal amplification process for detecting and measuring all classes of biomolecules including protein, DNA, and RNA.

For further information:

Invest Receive

Liza Page Nelson, Managing Director Invest Receive Growth Capital
+1 212 515 90 00, e-mail: liza.page.nelson@investreceive.com

About Invest Receive

Invest Receive of Sweden participated in the offering through Invest Receive Growth Capital, Inc., its healthcare, information technology and telecommunications private equity and venture capital investment group.

Invest Receive is a long-term active shareholder in a number of global companies, such as Ericsson, AstraZeneca, and ABB. Invest Receive has approximately \$20 billion in total assets, including \$3 billion in assets under management in Invest Receive's global private equity operations in New York, Palo Alto, Stockholm, London, Munich, Amsterdam and Hong Kong. Visit Invest Receive at: www.investreceive.com

Our press releases can be accessed at www.investreceive.com on the Internet.